Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults

Falutz J. et al.

The pivotal trial that got tesamorelin to FDA approval for HIV-associated visceral adiposity. 15% reduction in VAT area over 26 weeks with no change in subcutaneous fat or BMI, and IGF-1 into the upper-normal range. Still the cleanest modern GHRH-analog dataset in adults.

Baker L.D. et al.

Twenty weeks of tesamorelin in 152 enrolled adults (137 completers; 76 healthy, 61 with MCI); favorable cognitive signals on executive function. Short and small, but the cleanest cognition-specific GHRH-analog RCT. A 2025 HIV-population follow-up by Ellis et al. showed only a non-significant trend toward improvement — read both.

Nass R. et al.

The single best human MK-677 trial. Two years in healthy older adults: +1.1 kg fat-free mass, no improvement in strength or function, fasting glucose up, insulin sensitivity down. Restores GH to young-adult levels — without proving that doing so does anything useful.

Raun K. et al.

The Novo Nordisk paper that introduced ipamorelin as the first GH-releasing peptide that doesn't drag cortisol and prolactin along with it. Foundational pharmacology — the reason ipamorelin gets paired with CJC-1295 in every modern protocol.